SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-031010
Filing Date
2024-03-05
Accepted
2024-03-05 16:10:40
Documents
16
Period of Report
2024-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247928d1_8k.htm   iXBRL 8-K 26409
2 EXHIBIT 99.1 tm247928d1_ex99-1.htm EX-99.1 195709
6 GRAPHIC tm247928d1_ex99-1img001.jpg GRAPHIC 12146
  Complete submission text file 0001104659-24-031010.txt   435049

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rigl-20240305.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20240305_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20240305_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT tm247928d1_8k_htm.xml XML 3630
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

IRS No.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 24720436
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)